跳至主要内容
临床试验/NCT03321318
NCT03321318Unknown1 期

AK-R215 Pharmacokinetic Study Pharmacokinetic Characteristics of AK-R215 in Comparison to Each Component Coadministered in Healthy Adult Male or Menopausal Female Valunteers.

Alvogen Korea1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2017年7月13日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
发起方
入组人数
52
试验地点
1
主要终点
AUC0-t

研究概览

简要总结

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of AK-R215

详细描述

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the safety and pharmacokinetics characteristics after administration of fixed dose combination or loose combination of AK-R215 in healthy adult male or menopausal female volunteers

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • BW is above 50kg and BMI is between 18.5 and 30.0
  • Subject who agreed and signed on informed consent form prior to the study participation

排除标准

  • Presence or history of clinically significant disease
  • Treatment history of any drug which might affect IP within 10days
  • History of other study drugs within 12weeks

研究组 & 干预措施

B group

Active Comparator

reference drug, Bazedoxifene 20mg, Cholecalciferol 800IU

干预措施: AK-R215 (Drug)

A group

Experimental

AK-R215, test drug

干预措施: AK-R215 (Drug)

A group

Experimental

AK-R215, test drug

干预措施: Bazedoxifene 20 mg (Drug)

A group

Experimental

AK-R215, test drug

干预措施: Cholecalciferol 800IU (Drug)

B group

Active Comparator

reference drug, Bazedoxifene 20mg, Cholecalciferol 800IU

干预措施: Bazedoxifene 20 mg (Drug)

B group

Active Comparator

reference drug, Bazedoxifene 20mg, Cholecalciferol 800IU

干预措施: Cholecalciferol 800IU (Drug)

结局指标

主要结局

AUC0-t

时间窗: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96, 120h

Cmax

时间窗: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96, 120h

次要结局

  • Tmax(0, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96, 120h)
  • T1/2(0, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96, 120h)
  • AUCinf,(0, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96, 120h)

研究者

发起方
Alvogen Korea
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

AK-R215 Pharmacokinetic Study Phase I | 临床试验